Filtered By:
Condition: Thrombosis
Procedure: Heart Valve Surgery

This page shows you your search results in order of date.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Outcomes of aortic valve-sparing root replacement with cusp repair in connective tissue disease
CONCLUSION: Remodelling and aortic valve repair showed excellent durability at 5 years, even in connective tissue disorders.PMID:37640626 | DOI:10.1016/j.acvd.2023.07.005
Source: Archives of Cardiovascular Diseases - August 28, 2023 Category: Cardiology Authors: Pichoy Danial Pierre Demondion Mathieu Debauchez Pascal Leprince Emmanuel Lansac Source Type: research

Sociodemographic disparities in concomitant left atrial appendage occlusion during cardiac valve operations
by Ayesha P. Ng, Nikhil Chervu, Yas Sanaiha, Amulya Vadlakonda, Elsa Kronen, Peyman Benharash BackgroundSociodemographic disparities in atrial fibrillation (AF) management and thromboembolic prophylaxis have previously been reported, which may involve inequitable access to left atrial appendage occlusion (LAAO) during cardiac surgery. The present study aimed to evaluate the association of LAAO utilization with sex, race, and hospital region among patients with AF undergoing heart valve operations. MethodsAdults with AF undergoing valve replacement/repair in the 2012 –2019 National Inpatient Sample were identified and str...
Source: PLoS One - May 25, 2023 Category: Biomedical Science Authors: Ayesha P. Ng Source Type: research

Stroke and Noninfective Native Valvular Disease
AbstractPurpose of ReviewEmbolic stroke of undetermined source is a challenging clinical entity. While less common than atrial fibrillation and endocarditis, many noninfective heart valve lesions have been associated with stroke and may be considered as culprits for cerebral infarcts when other more common causes are excluded. This review discusses the epidemiology, pathophysiology, and management of noninfective valvular diseases that are commonly associated with stroke.Recent FindingsCalcific debris from degenerating aortic and mitral valves may embolize to the cerebral vasculature causing small- or large-vessel ischemia...
Source: Current Cardiology Reports - March 27, 2023 Category: Cardiology Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock after valve replacement
CONCLUSIONS: Outcomes of ECMO in patients with prosthetic valves are comparable between bioprosthetic and mechanical valves. Thrombosis might occur in both valve types and was associated with high mortality. ECMO could affect the long-term durability of the bioprosthetic valves.PMID:36645201 | DOI:10.1177/02676591231152723
Source: Perfusion - January 16, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Amr A Arafat Mohammed AlBarrak Musab Kiddo Khaled Alotaibi Huda H Ismail Adam I Adam Mohamed A Aboughanima Monirah A Albabtain Tarek M Tantawy Claudio Pragliola Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Subsequent cardiac surgery after transcatheter aortic valve implantation: Indications and outcomes
ConclusionsSubsequent open-cardiac surgery after TAVI is rare, but may urgently become necessary due to TAVI related complications or progressing other cardiac pathologies. Despite a substantial early attrition rate clinical outcome is acceptable and a relevant number of these high-risk patients can be discharged even after emergency conversions. The option of subsequent surgical conversion remains.
Source: Journal of Cardiac Surgery - November 15, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Albi Fagu, Matthias Siepe, Murat Uzdenov, Dominik Dees, Stoyan Kondov, Friedhelm Beyersdorf, Bartosz Rylski, Martin Czerny, Franz ‐Josef Neumann, Maximilian Kreibich, Tim Berger Tags: ORIGINAL ARTICLE Source Type: research